The Pre-treatment Gut Microbiome is Associated with Lack of Response to Methotrexate in New Onset Rheumatoid Arthritis.

Autores de IIS La Fe

• 

  Antonio Pineda Lucena

  Autor

Participantes ajenos a IIS La Fe

• Artacho, Alejandro
• Isaac, Sandrine
• Nayak, Renuka
• Flor-Duro, Alejandra
• Alexander, Margaret
• Koo, Imhoi
• Manasson, Julia
• Smith, Philip B
• Rosenthal, Pamela
• Homsi, Yamen
• Gulko, Percio
• Pons, Javier
• Puchades-Carrasco, Leonor
• Izmirly, Peter
• Patterson, Andrew
• Abramson, Steven B
• Turnbaugh, Peter J
• Ubeda, Carles
• Scher, Jose U

Grupos

• Unidad de Descubrimiento de Fármacos (UDF)

  Investigador Principal

  Leonor Puchades Carrasco

Abstract

Although oral methotrexate (MTX) remains the anchor drug for RA, up to 50% of patients do not achieve a clinically adequate outcome. Concomitantly, there is a lack of prognostic tools for treatment response prior to drug initiation. Here we study whether inter-individual differences in the human gut microbiome can aid in the prediction of MTX efficacy in new-onset RA (NORA).